If the exosome activity is not "near term" as Zacks suggests then we have only a few options in the spring:
Hep C moves forward and partners need to be prominent
Someone OTHER THAN Aethlon needs a good deal, a breakthrough or big publicity and we ride their wave. I don't see any other options.
Some of us have asked the question before---is the only real driver cancer now? Wasn't there chatter about concussions and an announcement from the NFL during the Super Bowl? Sepsis? Sure there's a market for Hep C outside of the improved drugs coming out with Gilead, etc. but isn't the market much smaller now?
The dilution of shares has to subside. 20% of the exosome subsidiary is now owned by someone else. I'd be interested in an alternative take on this view; shoot, I'd take some serious discussion about anything at this point.
I appreciate your post. I don’t believe anyone not even JJ knows with any certainty the moment when Aethlon will be the success we all want it to be, if he knew he couldn’t tell us anyway. That being said
It looks to me that he’s trying to meet the requirements for a NASDAQ listing. When he succeeds we will all benefit in a very big way. Mom and Pop day traders just don’t cut it.
Aethlon needs to set a date for the FDA trial to begin. The announcement should be released very shortly as results were anticipated in mid May. Waiting months instead of years as long term investors have done still is nerve wracking. March should be a turn the corner beginning for investors. Good luck to one and all.